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ABSTRACT
Objectives: Polyoxometalates (POMs) are proved to be important for applications in medicine and in material science. Here, we represent 
nanocomposite formation of tungsten-containing potent anticancer polyanion, K6H [CoW11O39 (CpTi)].13H2O (CoW11CpTi) with biocompatible 
ChitosanYC-100 (CSYC100) with the goal to reduce its heavy metal toxicity.
Methods: Synthesis of “POM-CSYC100 nanocomposite” was attained without the aid of any cross-linker through electrostatic interaction technique. 
Nanocomposites were characterized using Fourier transform infrared spectroscopy, dynamic light scattering, transmission electron microscopy, and 
thermogravimetric analysis. The release profile recorded was slow and sustained at physiological pH. In vitro cytotoxicity assays which show an 
attribute to reduce the toxicity of these POM were performed on C2C12 (mouse myoblast cell line) and A-549 (lung cancer cell line), which proved the 
reduced toxicity of nanocomposites as compared to the bare drugs.
Results: Sustained release studies showed there was a slow and steady release of CoW11CpTi for 11 hrs, with the 98% of collective release at the 
end. From in vitro cytotoxic assay, it was deduced that CoW11CpTi -CSYC100 nanocomposite at the concentrations of 1.25 mM, and lower did not 
exhibit toxic effect on C2C12 cells as 95% total C2C12 cell mass remained viable. While in the case of A549 cells highest 5 mM concentration of bare 
CoW11CpTi is toxic to the cancer cells and after encapsulation cell viability increases from 10% to 55%.
Conclusion: Thus, this study has designated the probability of using POM-chitosan nanocomposite for less toxic and effective biomedicinal applications.
Keywords: Anticancer, Chitosan, Nanocomposite, In vitro cytotoxicity, Drug release.
INTRODUCTION
Polyoxometalates (POMs) can be defined as “early transition metal 
oxygen clusters.” POMs have gained tremendous attention because of 
their mutable uses in the areas of novel drug development, material 
sciences, and in industrial catalyst [1]. The use of POMs in latent 
applications for human medicine is growing exponentially and are 
recently published in the literatures [2,3]. The toxicity due to the 
presence of metal ions is the major drawback of these precious 
medicinal molecules. To lower down the toxicity, it needs to be 
conjugate/encapsulate in some biopolymeric delivery vehicle.
Chitosan and its derivatives linger to attract noteworthy attention 
as a potent drug transporter with remarkable biocompatibility 
along with appreciable cellular uptake rates [4-6]. Chitosan is a 
carbohydrate heteropolymer composed of glucosamine and N-acetyl 
glucosamine linked by β 1-4 glucosidic bonds as a repeating unit. 
Chitosan is developed from chitin by its N-deacetylation. Chitin a 
structural polysaccharide found in the exoskeleton of shrimps and 
shells of crabs and the second most abundant polysaccharide found 
in nature after cellulose [7]. This versatile feature has been used 
in this study to beat the significant biomedical potential of POMs 
by their encapsulation in chitosan YC-100 (CSYC100) matrix. The 
chosen title anion K6H[CoW11O39(CpTi)].13H2O, hereafter denoted as 
(CoW11CpTi) is reported to be the most potent anticancer POM among 
the family of CpTi substituted POMs studied so far. It is reported that 
polyoxotungstate CoW11CpTi curiously decreased tumor weight of the 
rats bearing HLC (colon cancer cell), HL-60 (leukemia), and SSMC-7721 
(liver cancer cell) where the experimental results were procured using 
the animal tumor implantation method. The in vivo anticancer efficacy 
of CoW11CpTi is at par with the clinical anticancer drugs 5-fluorouracil 
and CP (abbreviation of cyclophosphamide), but the cytotoxicity of 
CoW11CpTi is reported to be less than them [8].
The research described in this report is focused to prepare the 
nanocomposite of low molecular weight carbohydrate polymer 
CSYC100 and an anticancer POM CoW11CpTi. The primary agenda 
of this research is to portray reduction in the metallic toxicity 
of POMs by its involvement in the formation of nanocomposite 
with CSYC100. To support this hypothesis, CoW11CpTi-CSYC100 
nanocomposites were prepared and its toxicity was assessed in 
vitro on cell line C2C12 (normal myoblast cell line) and A-549 
(adenocarcinomic human alveolar basal epithelial cells-lung 
cancer cell line). To the best of our knowledge, this the first report 




CSYC100 is a low molecular weight chitosan (~10000 g/mol) and highly 
water soluble and purchased from Sigma-Aldrich, Steinheim, Germany. 
Other chemicals required for synthesis of POMs, and other studies were 
bought commercially from Sigma-Aldrich.
Preparation of POMs
Polyoxotungstate CoW11CpTi was synthesized according to the 
procedure described by Wang et al. in 2003 [8].
Synthesis of CSYC100/CoW11CpTi complexes
To synthesize CoW11CpTi-CSYC100 nanocomposites, 50 mg CSYC100 
was dissolved in 70 ml double distilled water. The mixture was stirred 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16721
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until the CSYC100 complete dissolve, and the clear solution is observed. 
The solution was then filtered to remove any suspended particles. 
CSYC100 filtrate was further used to prepare nanocomposites of POMs. 
170 mg (0.39 mM) CoW11CpTi was dissolved in 2 mL double distilled 
water separately. CoW11CpTi solution was then added dropwise 
with stirring into the CSYC100 solution under controlled sonication, 
resulting in the formation of stable colloidal suspension of CoW11CpTi-
CSYC100 nanocomposite. This suspension was centrifuged for 
20 minutes at 12,000 rpm (18,000 g) to collect the CoW11CpTi-CSYC100 
nanocomposites obtained as pellet. The supernatant was discarded, 
and pellet of CoW11CpTi-CSYC100 was recovered, dried and used for 
further studies.
Physicochemical characterization of POM-CSYC100 nanocomposites
Morphology and particle size of the nanocomposites was analyzed 
by transmission electron microscopy (TEM) (Model-Philips Tecnai 
20). The particle size distribution and hydrodynamic diameter size 
were determined by dynamic light scattering (DLS) method using 
particle size analyzer (Model: Malvern Zetasizer). Fourier transformed 
infrared (FT-IR) spectroscopy was used to recognize the signature 
absorption peaks, by recording the spectral scan ranging from 4000 to 
400/cm using the instrument thermo scientific nicolet-6700 class-1. 
Thermal strength of the nanocomposites was analyzed using the 
thermogravimetric technique (Mettler-Toledo TGA/DSC-1 Stare system) 
in nitrogen atmosphere from 25°C to 800°C temperature with a rate of 
10°C/min.
In vitro release of CoW11CpTi from CSYC100 matrix
The in vitro release of CoW11CpTi from the nanocomposite was carried 
out at 37°C in phosphate buffered saline (PBS) of pH 7.4 containing 
lysozyme (1.6 g/mL). The nanocomposites were centrifuged for 
15 minutes at 12000 rpm. The supernatant was transferred to the 
fresh tube for recordicg its ultraviolet (UV)-visible spectra using 
spectrophotometer and recovered pellet was redispersed in PBS. 
Similarly, the same procedure was repeated at the programed time 
intervals, where the samples were centrifuged at 12000 rpm (18000 g) 
for 15 minutes, and the supernatant was analyzed using UV-visible 
spectrophotometer to determine the amount of POM released from 
the nanocomposite, after which the sample was swapped back into the 
solution. The absorbance obtained was compared with concentration 
dependent standard curve of CoW11CpTi was to determine its release at 
different time intervals.
Cell culture
Under this study, we used C2C12 (Normal myoblast cells) and A-549 
(adenocarcinomic human alveolar basal epithelial cells-lung cancer 
cell line), acquired from national center for cell sciences (NCCS), Pune, 
India. The cells were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM, GIBCO) complemented with 10% fetal bovine serum (GIBCO) 
and 1% antibiotic-antimycotic (anti-anti, GIBCO) at 37°C in humidified 
atmosphere with 5% CO2 in an incubator. The media was refilled at the 
interval of 24 hrs, and the cells were sub-cultured when 90% confluency 
was attained.
In-vitro cytotoxicity analysis using [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] (MTT) assay
Cytotoxicity on C2C12 mouse myoblast cells of the bare CoW11CpTi 
and CoW11CpTi-CSYC100 nanocomposites were analyzed using 
MTT assay. MTT assay is a colorimetric assay based on the selective 
ability of viable cells to reduce the tetrazolium component of MTT 
into purple colored formazan crystals [9-11]. Cells were seeded 
into a 96 well plate at a seeding density of 10000 cells/ml. MTT dye 
(5 mg/mL) was added into each well after mixing and incubating 
the cell with various concentrations of CoW11CpTi-CSYC100 
nanocomposites and bare POMs (5 mM-0.019 mM) at specific 
intervals, in triplicates for 24 hrs. The percentage cell viability was 
determined using microplate reader (Microtek Power Wave XS US) 
by recording the  optical absorbance at 570 nm comparative to the 
untreated cells.
Analysis of variance was carried out using triplicate value to identify a 
significant difference in the cell viability between POM-CSYC100 nano-
composites and bare POM. Mean values of triplicates were compared 
at significance levels of 5%, 1%, and 0.1% least significant difference.
RESULTS AND DISCUSSION
Physicochemical characterization of POM-CSYC100 
nanocomposites
CoW11CpTi were prepared and further used to synthesize hybrid 
CoW11CpTi-CSYC100 nanocomposites with primary agenda to 
reduce their toxicity. In-vitro cytotoxicity of CoW11CpTi-CSYC100 
nanocomposite and bare CoW11CpTi were examined on C2C12 
(normal myoblast cells). The nanocomposites were prepared by an 
electrostatic interactions taking benefit of the negatively charged 
CoW11CpTi and positively charged CSYC100. Subsequently, CoW11CpTi 
possessing negative charge is capable of forming stable colloids with 
the biopolymer CSYC100 bearing a positive charge.
Bare CoW11CpTi was characterized using FT-IR spectroscopy. Further, it 
was used to prepared nanocomposite with CSYC100. Once the CoW11CpTi-
CSYC100 nanocomposites were prepared; FT-IR spectroscopy was done 
to confirm the successful nanocomposite development.
(Fig. 1) describes the FT-IR spectrum of bare CoW11CpTi, native 
CSYC100 and CoW11CpTi -CSYC100 nanocomposites. FT-IR spectrum of 
CSYC100 is represented in Fig. 1a, which signifies all the characteristic 
peaks of chitosan at 3420/cm appeared, and this can be credited to the 
-NH2 and -OH groups stretching vibration and a peak at 1620/cm for 
the amide similar to as characterized earlier [12-14]. FT-IR spectrum of 
bare CoW11CpTi denoted in Fig. 1c portrays characteristic peak sharp 
absorption at 1620/cm. This feature is typical of the C-C stretching 
for ɳ5-C5 H5 ligand attached to Ti11 which exhibit the presence of 
cyclopentadienyl ligand.
The spectrum of CoW11CpTi-CSYC100 nanocomposite (Fig. 1b) shows 
all the representative peaks existing in bare CoW11CpTi representing 
successful complex development. Furthermore, the peak at 1060/cm 
corresponds to the bridge oxygen (C–O–C) stretching bands [12-14].
Fig. 2 represents the TEM images of CoW11CpTi -CSYC100 
nanocomposite. It is a clear evident from the images that approximately 
all composites obtained by this technique were (1) monodispersed (2) 
possessed spherical shape morphology and (3) had sizes ranging from 
35 to 80 nm in the diameter.
DLS analysis portrayed hydrodynamic size of the nanocomposites 
(Fig. 3). DLS analysis unveiled that 98% or more particles possess 
Fig. 1: Comparative Fourier transformed infrared spectrum 
of (a) ChitosanYC-100 (CSYC100), (b) CoW11CpTi-CSYC100 
nanocomposite, (c) bare CoW11CpTi
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hydrodynamic diameter size <100 nm (Number % distribution). 
CoW11CpTi-CSYC100 nanocomposite, size distribution of particles 
ranges from 42.82 to 72.82 nm, and 35.9% (highest) particles are of 
50.75 d nm size.
Thermograms of CSYC100, CoW11CpTi-CSYC100 nanocomposite and 
bare CoW11CpTi, shown in Fig. 4 describes that the thermal strength 
of the nanocomposite is better when compared to the bare CSYC100. 
This may be credited due to the formation of a complex by CSYC100 
with thermally stable CoW11CpTi having lesser degradation as those 
are heavy metal salts. From the thermogram of CSYC100 in Fig. 4, 
the degradation observed up to 100°C can also be due to the loss in 
moisture and then polymer remains stable till 228°C as there is 
minimal change in the weight loss from 100 to 228°C. Afterward, an 
exponential degradation of was observed up to 380°C which may be 
due to degradation of CSYC100 polymeric structure.
In case of nanocomposite, thermogram showed the degradation 
starting at 180°C, further with a slow degradation till 320°C. The 
percentage weight residual at 900°C for the nanocomposite was more 
when related to CSYC100. Furthermore, the sharpness of the curve was 
reduced for nanocomposite, representing its debilitated degradation 
in comparison to that of bare CSYC100. CoW11CpTi exhibited a small 
degradation due to the moisture loss at around 100°C. Further, there 
was no degradation observed up to 900°C which represents ∼90% 
of the particles did not undergo any degradation and stayed stable. 
Basically, the thermal stability of CSYC100 is significantly improved 
when developing composites with the thermally stable CoW11CpTi.
To study the release of CoW11CpTi from nanocomposites, lysozyme 
was dissolved in PBS at pH 7.4, and this solution was used as release 
medium. Lysozyme was used as it enzymatically degradation of the 
glycosidic bonds in CSYC100 polymer. Lysozyme concentration was 
adjusted to mimic the in vivo system. Here, lysozyme weakens the 
electrostatic interaction between CoW11CpTi and CSYC100 which 
would cause its controlled release from composites. It was seen that 
there was a slow and steady release of CoW11CpTi for 11 hrs, with the 
98% of collective release at the end (Fig. 5).
Results of MTT assay were performed to study the toxicity of bare 
CoW11CpTi and hybrid CoW11CpTi -CSYC100 nanocomposites on C2C12 
and A549 cell line is represented in (Fig. 6). Concentrations of bare 
CoW11CpTi and CoW11CpTi-CSYC100 were varied from 0.019 mM to 
5mM range. At very high concentration of 5 mM, CoW11CpTi and hybrid 
CoW11CpTi-CSYC100 nanocomposite were toxic to the C2C12 and 
A549 cells. However, there was significant variation in the percent (%) 
viability of C2C12 cells and A549 cells at their lower concentrations. 
Calculated IC50 values for bare CoW11CpTi and hybrid CoW11CpTi-
CSYC100 nanocomposite on C2C12 cells were 4.8 mM and 5.3 mM; 
similarly, IC50 values for these compounds on A549 were 0.9 and 
4.9 mM, respectively. This show Hybrid POM was less toxic at higher 
concentrations as compared to bare POM. Furthermore, cancerous cells 
A459 can easily be inhibited by CoW11CpTi-CSYC100 nanocomposite at 
very low concentrations where normal C2C12 cells remain viable and 
unaffected.
DISCUSSION
Initially, the research portrayed in this manuscript deals with the 
synthesis of CoW11CpTi. This desired POM was synthesized using the 
Fig. 2: Transmission electron microscopy images of CpTi-
ChitosanYC-100 nanocomposite
Fig. 3: Particle size distribution (number %) using dynamic light 
scattering analysis of CoW11CpTi-ChitosanYC-100 nanocomposite
Fig. 4: Comparative thermo gravimetric analysis of 
ChitosanYC-100 (CSYC100), CoW11CpTi-CSYC100 nanocomposite, 
bare CoW11CpTi
Fig. 5: Release of CoW11CpTi from CoW11CpTi-ChitosanYC-100 
nanocomposite
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standard protocol reported by Wang et al. [8]. Successful synthesis of 
CoW11CpTi was confirmed by comparing the FT-IR spectra of the same 
POM originally synthesized by Wang et al. [8].
Once the desired POM (CoW11CpTi) was synthesized, its nanocomposite 
was synthesized. This is the first report for the synthesis of 
nanocomposites using P2W17Ni. To categorize any composite particles 
as “nano” requires strict implementation on the limitation of the particle 
size which is to be <100 nm. Hence, the first important characterization 
was to study the size of the CoW11CpTi-CSYC100 formed. With the aid 
of particle size analysis by DLS and by TEM imaging, it was noted that 
the average size of CoW11CpTi-CSYC-100 composites was 50 nm. Thus, 
with this data, CoW11CpTi-CSYC100 composites can be classified as 
“nano” in nature [15]. For successful nanocomposite formation to have 
occurred, they were characterized for the linking of POM with CSYC100 
using FT-IR spectral analysis where FT-IR spectrum signifies all the 
characteristic peaks of chitosan at 3420/cm appeared, and this can be 
credited to the -NH2 and -OH groups stretching vibration and a peak at 
1620/cm for the amide similar to as characterized by Anitha et al. [1]; 
this proves that CSYC100 forms linkage with POM.
Thermograms of CSYC100, CoW11CpTi-CSYC100 nanocomposite, 
and bare CoW11CpTi describes that the thermal strength of the 
nanocomposite is better when compared to the bare gelator. This may be 
credited due to the formation of a complex by CSYC100 with thermally 
stable CoW11CpTi having lesser degradation as those are heavy metal 
salts similar results are also reported by Geisberger et al. [3].
Release of CoW11CpTi from CoW11CpTi-CSYC100 nanocomposite was 
analyzed to understand the profile of POM release from nanocomposite, 
here it was observed that the release of POM occurred till 11 hrs under 
simulated physiological conditions. In other words, for 98% of POM to 
escape from the matrix of nanocomposites requires 11 hrs. This is greatly 
significant for drug development as POMs at high dosages are lethal of 
the cells of the body, so its sustained release is inevitable [8]. This can be 
seen when the cytotoxicity of bare CoW11CpTi and CoW11CpTi -CSYC100 
nanocomposite was tested in vitro on normal myoblast cell lines C2C12 
and A549 lung cancer cell line using MTT assay. Results on normal 
myoblast cell lines C2C12 are essentially important because it mimics 
the behavior of normal healthy cells of the body. It was observed that 
CoW11CpTi-CSYC100 nanocomposite was comparatively less toxic than 
bare CoW11CpTi; this can be due to the phenomena of sustain release 
of CoW11CpTi from the CSYC100 nanocomposites [6,8,10,13]. Despite 
such positive results, extensive research is still needed to be done on 
model organisms to make highly specific and finely tuned POM baring 
nanocomposites as a futuristic medicine.
CONCLUSIONS
Under this study, cytotoxicity of an anticancer POM, CoW11CpTi was 
reduced by preparing their nanocomposite using CSYC100. To start 
with, bare CoW11CpTi was prepared and their purity was analyzed using 
FT-IR. This POM was then used to prepare nanocomposites namely 
CoW11CpTi-CSYC100 which was characterized using DLS, FT-IR, TEM, 
and TGA analysis. The release profile of CoW11CpTi from CoW11CpTi-
CSYC100 nanocomposite was recorded at physiological pH conditions 
which showed CoW11CpTi was released from CSYC100 matrix at slow 
rate, and thus, we concluded that the release was sustained. Finally, 
the cytotoxicity assays of CoW11CpTi-CSYC100 nanocomposite were 
performed on normal myoblast cell lines C2C12 and A549 lung cancer 
cell line. CoW11CpTi -CSYC100 nanocomposite at the concentrations of 
1.25 mM and lower did not exhibit toxic effect on C2C12 cells as 95% 
total C2C12 cell mass remained viable. While in case of A549 cells 
highest 5 mM concentration of bare CoW11CpTi is toxic to the cancer 
cells and after encapsulation cell viability increases from 10% to 55%. 
Cytotoxicity assays show that CoW11CpTi in complex with CSYC100 
had reduced toxic effect on C2C12 mouse myoblast cells. Thus, this 
study has designated the feasibility of consuming CoW11CpTi-CSYC100 
chitosan nanocomposite for lesser toxic biomedicinal applications.
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